This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Arena Bulls, Bears Endure Annoyingly Long Wait for Belviq Launch

Stock quotes in this article: ARNA, VVUS

SAN DIEGO ( TheStreet) -- Arena Pharmaceuticals' (ARNA) bulls and bears agree on one thing: The long wait to finalize DEA scheduling for the weight-loss pill Belviq is annoying.

Without a DEA schedule determining the abuse and addiction potential of Belviq, Arena and its marketing partner Eisai cannot begin to sell the weight-loss pill. FDA approved Belviq on June 27, 2012, so the wait for DEA scheduling has now dragged on for nine and half months.

The DEA doesn't operate under any time constraints when it comes to finalizing drug schedules, but a six or seven-month review is pretty typical. For some unknown reason, DEA is taking a longer time to push Belviq out the door.

Arena has already manufactured and shipped Belviq to Eisai, which is ready for commercial launch within days of receiving the final word from the DEA, says Arena spokeswoman Cindy McGee. Arena is unaware of any problem that would be delaying the DEA decision, she adds. Once launched, Belviq will compete against Vivus' (VVUS) weight-loss pill Qsymia.

The long wait has led to some speculation that DEA may be reconsidering its initial recommendation to place Belviq in the Schedule IV "low potential for abuse" category, perhaps bumping up to Schedule III, which consists of drugs with "moderate or low physical dependence or high psychological dependence."

Practically speaking, slotting Belviq as a Schedule III or Schedule IV drug doesn't matter because both categories allow for five prescription refills in six months. Either way, doctors and patients will have relatively unfettered access to Belviq. Only if DEA chooses to slam Belviq with a Schedule II designation would the drug's access be restricted, but no one really believes that's going to happen.

Arena bulls and bear are hating the wait equally but for very different reasons. The bulls believe Belviq is a blockbuster weight-loss drug in the making; bears insist Belviq's middling efficacy dooms the drug to be a commercial flop.

Until Belviq hits the market, neither side can declare victory. Arena's stock price remains in stasis, trading between $8-9 per share since last August.

Annoying.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs